Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline

医学 指南 加药 养生 重症监护医学 内科学 儿科 病理
作者
Linan Zeng,Michael Walsh,Gordon Guyatt,Reed Siemieniuk,David Collister,Michelle Booth,Paul Brown,Lesha Farrar,Mark Farrar,Tracy Firth,Lynn A. Fussner,Karin Kilian,Mark A. Little,Thomas A. Mavrakanas,Reem A. Mustafa,Maryam Piram,Lisa K. Stamp,Yingqi Xiao,Lyubov Lytvyn,Thomas Agoritsas
标识
DOI:10.1136/bmj-2021-064597
摘要

Abstract Clinical questions What is the role of plasma exchange and what is the optimal dose of glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)? This guideline was triggered by the publication of a new randomised controlled trial. Current practice Existing guideline recommendations vary regarding the use of plasma exchange in AAV and lack explicit recommendations regarding the tapering regimen of glucocorticoids during induction therapy. Recommendations The guideline panel makes a weak recommendation against plasma exchange in patients with low or low-moderate risk of developing end stage kidney disease (ESKD), and a weak recommendation in favour of plasma exchange in patients with moderate-high or high risk of developing ESKD. For patients with pulmonary haemorrhage without renal involvement, the panel suggests not using plasma exchange (weak recommendation). The panel made a strong recommendation in favour of a reduced dose rather than standard dose regimen of glucocorticoids, which involves a more rapid taper rate and lower cumulative dose during the first six months of therapy. How this guideline was created A guideline panel including patients, a care giver, clinicians, content experts, and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. The recommendations are based on two linked systematic reviews. The panel took an individual patient perspective in the development of recommendations. The evidence The systematic review of plasma exchange identified nine randomised controlled trials (RCTs) that enrolled 1060 patients with AAV. Plasma exchange probably has little or no effect on mortality or disease relapse (moderate and low certainty). Plasma exchange probably reduces the one year risk of ESKD (approximately 0.1% reduction in those with low risk, 2.1% reduction in those with low-moderate risk, 4.6% reduction in those with moderate-high risk, and 16.0% reduction in those with high risk or requiring dialysis) but increases the risk of serious infections (approximately 2.7% increase in those with low risk, 4.9% increase in those with low-moderate risk, 8.5% increase in those with moderate-high risk, to 13.5% in high risk group) at 1 year (moderate to high certainty). The guideline panel agreed that most patients with low or low-moderate risk of developing ESKD would consider the harms to outweigh the benefits, while most of those with moderate-high or high risk would consider the benefits to outweigh the harms. For patients with pulmonary haemorrhage without kidney involvement, based on indirect evidence, plasma exchange may have little or no effect on death (very low certainty) but may have an important increase in serious infections at 1 year (approximately 6.8% increase, low certainty). The systematic review of different dose regimens of glucocorticoids identified two RCTs at low risk of bias with 704 and 140 patients respectively. A reduced dose regimen of glucocorticoid probably reduces the risk of serious infections by approximately 5.9% to 12.8% and probably does not increase the risk of ESKD at the follow-up of 6 months to longer than 1 year (moderate certainty for both outcomes). Understanding the recommendation The recommendations were made with the understanding that patients would place a high value on reduction in ESKD and less value on avoiding serious infections. The panel concluded that most (50-90%) of fully informed patients with AAV and with low or low-moderate risk of developing ESKD with or without pulmonary haemorrhage would decline plasma exchange, whereas most patients with moderate-high or high risk or requiring dialysis with or without pulmonary haemorrhage would choose to receive plasma exchange. The panel also inferred that the majority of fully informed patients with pulmonary haemorrhage without kidney involvement would decline plasma exchange and that all or almost all (≥90%) fully informed patients with AAV would choose a reduced dose regimen of glucocorticoids during the first 6 months of therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雨洋完成签到,获得积分10
1秒前
chi完成签到 ,获得积分10
2秒前
还单身的湘完成签到,获得积分10
4秒前
fyjlfy完成签到 ,获得积分10
4秒前
深情安青应助Nayvue采纳,获得10
5秒前
研友_Y59785完成签到,获得积分0
5秒前
Xiaoxiao发布了新的文献求助10
6秒前
初初见你完成签到,获得积分10
13秒前
16秒前
思源应助淡淡月饼采纳,获得20
16秒前
dd完成签到 ,获得积分10
17秒前
Nayvue发布了新的文献求助10
21秒前
未来的幻想完成签到,获得积分10
23秒前
Kvolu29完成签到,获得积分10
24秒前
长理物电强完成签到,获得积分10
25秒前
若安在完成签到,获得积分10
26秒前
完美世界应助潘特采纳,获得10
27秒前
拼搏问薇完成签到 ,获得积分10
27秒前
单薄乐珍完成签到 ,获得积分0
30秒前
张静枝完成签到 ,获得积分10
30秒前
六步郎完成签到,获得积分10
30秒前
啊怙纲完成签到 ,获得积分10
32秒前
量子星尘发布了新的文献求助10
34秒前
scott_zip完成签到 ,获得积分10
35秒前
gxl完成签到,获得积分0
39秒前
xxx完成签到 ,获得积分10
42秒前
42秒前
努力生活的小柴完成签到,获得积分10
44秒前
46秒前
tangyong完成签到,获得积分10
48秒前
长安发布了新的文献求助10
48秒前
SucceedIn完成签到,获得积分10
49秒前
50秒前
53秒前
海洋岩土12138完成签到 ,获得积分10
54秒前
lzz完成签到 ,获得积分10
54秒前
冬雪完成签到,获得积分10
58秒前
woommoow完成签到,获得积分10
58秒前
aaatan完成签到 ,获得积分10
58秒前
lynn完成签到,获得积分10
59秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022